21 aug: Bang & Olufsen A/S – Vedtægter
22 aug: Ambu A/S: Ambu investerer i en 100% direkte salgs-organisation ti..
21-08-2019 23:59:36

Genmab Announces Preliminary Data to be Presented at IASLC 2019 World Conference on Lung Cancer

Media Release

Copenhagen, Denmark, August 21, 2019

Genmab A/S (Nasdaq: GMAB) announced today that preliminary data from the Phase I/II trial of enapotamab vedotin in advanced non-small cell lung cancer (NSCLC) has been accepted for oral presentation at the International Association for the Study of Lung Cancer 2019 World Conference on Lung Cancer (IASLC 2019 WCLC) taking place from September 7-10, 2019 in Barcelona, Spain. Meeting abstracts are currently accessible form the IASLC 2019 WCLC website, https://wclc2019.iaslc.org/.

“We are honored that early data from enapotamab vedotin was chosen for oral presentation at the IASLC 2019 WCLC. The selection of this data for presentation also supports our belief in the potential of this first-in-class compound for patients with advanced non-small cell lung cancer progressing on chemotherapy and a checkpoint inhibitor; we look forward to more advanced and complete data becoming available in the future” said Jan van de Winkel, Ph.D., Chief Executive Officer of Genmab.

Enapotamab vedotin abstract to be presented:

First-in-human Phase 1/2 trial of anti-AXL antibody–drug conjugate enapotamab vedotin in advanced NSCLC – Oral presentation, Sunday, September 8, 2019, 11:15 AM – 11:25 AM CEST. Full abstract available here.

About Genmab

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. Genmab is headquartered in Copenhagen, Denmark with core sites in Utrecht, the Netherlands and Princeton, New Jersey, U.S.

Contact:          

Marisol Peron, Corporate Vice President, Communications & Investor Relations

T: +1 609 524 0065; E: mmp@genmab.com

For Investor Relations:

Andrew Carlsen, Senior Director, Investor Relations

T: +45 3377 9558; E: acn@genmab.com

This Media Release contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s final prospectus for our U.S. public offering and listing and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. Genmab does not undertake any obligation to update or revise forward looking statements in this Media Release nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody®; HexElect®; and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen Pharmaceutica NV.

Media Release no. 11

CVR no. 2102 3884

LEI Code 529900MTJPDPE4MHJ122

Genmab A/S

Kalvebod Brygge 43

1560 Copenhagen V

Denmark

Attachment

Primary Logo

Relateret indhold
16 sep - 
Mandagens aktier: Svingende Lundbeck endte lavere i rød..
16 sep - 
Aktier/middag: Lundbeck vender rundt og topper rødt C25..
16 sep - 
Aktier/åbning: Lundbeck helt i bund på milliardopkøb i ..
Relateret debat
21 sep - 
Nej, det skyldes Triple Witching Day, futures der udløb..
20 sep - 
http://www.aktieordbog.dk/lukkeauktion
20 sep - 
Hej Jeg er ny herinde og undrer mig over, når man betra..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
16 sep
GEN
GENMAB/GUGGENHEIM: LØFTER KURSMÅLET MED 12,4 PCT. 06:36 Finanshuset Guggenheim Securities løfter sit..
9
20 sep
GEN
http://www.aktieordbog.dk/lukkeauktion
3

OECD sænker global vækstprognose for de kommende år

19-09-2019 11:20:24
Organisationen for Økonomisk Samarbejde og Udvikling (OECD) sænker sin globale vækstprognose for de kommende år, idet organisationen nu ser yderligere risici i verdensøkonomien.OECD venter nu en global vækst i bruttonationalproduktet (BNP) på 2,9 pct. i år og 3,0 pct. næste år.Det er en nedrevidering fra henholdsvis 3,2 pct. og 3,4 pct. i den seneste prognose.For USA er vækstprognosen sænket til 2..

Aktier/tendens: Udsigt til rød start ovenpå FED-møde

19-09-2019 08:25:07
Der er umiddelbart udsigt til små fald fra starten af den danske aktiehandel torsdag, hvor øjne og ører kan rette sig mod Ørsted, Simcorp og Sydbank. Dermed følger markedet onsdagens tendens efter tilbagegang efter rentemødet i den amerikanske centralbank, Federal Reserve (Fed).Japanske aktier ligger højere, futures på amerikanske aktier ligger op til 0,4 pct. lavere, mens DAX-futuren ligger 0,1 p..

Lars Christensens Verden - Episode 26: Sidste uges quant quake varsler nye tider på de finansielle markeder

Relaterede nyheder
18-09-2019 19:17:00
Begivenheden er af nogle blevet omtalt som et jordskælv i de globale markeder, og nej det var ikke ECB's seneste rentebeslutning eller den renteforhøjelse eller -nedsættelse, Fed annoncerer onsdag aften, dansk tid. Det er heller ikke oliepriserne, der har bevæget sig voldsomt ovenpå weekendens angreb på de saudiske olieinstallationer og Trumps Iran-tweets i kølvandet herpå, men derimod det såkaldt..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge

Relaterede aktiekurser

Genmab A/S 1.402,00 1,4% Stigning i aktiekurs

Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
22. september 2019 07:52:04
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190829.2 - EUROWEB1 - 2019-09-22 07:52:04 - 2019-09-22 07:52:04 - 1 - Website: OKAY